Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Jason M Melear"'
Autor:
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovani, Xiaowei Zhang, Aileen Cohen, Jane Huang
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 301-304 (2023)
Externí odkaz:
https://doaj.org/article/61318e5dc11945ce8ecb239e81fc2c4b
Autor:
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Álvaro López-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Publikováno v:
Nature Medicine.
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratum
Autor:
Paul M. Barr, Stephen D. Smith, Mark J. Roschewski, Susan M. O’Brien, Jeff P. Sharman, Jason M. Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E. Spurgeon
Publikováno v:
Leukemia & Lymphoma. 63:1728-1732
Autor:
Ruth Plummer, Hendrik-Tobias Arkenau, Jordi Ferrer-Playan, Jason M. Melear, Alexander I. Spira, Ivan Diaz-Padilla, Giuseppe Locatelli, Jennifer Dong, Thomas Goddemeier, Ki Y. Chung, Emma Dean, Patricia Fleuranceau-Morel, Charles H. Redfern, Geoffrey I. Shapiro
Publikováno v:
Lung Cancer. 163:19-26
Objectives Berzosertib (formerly M6620, VX-970) is an intravenous, highly potent and selective, first-in-class ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. We assessed the safety, tolerability, preliminary efficacy, and phar
Autor:
Frederick Lansigan, D.J. Andorsky, Morton Coleman, Jeffrey P. Sharman, J. Li, Jr Ahn, Mecide Gharibo, Jason M. Melear, G.S. Nowakowski, Suzanne R. Fanning, Abdulraheem Yacoub, Mathias J. Rummel
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S73-(2021)
Objectives The combination of lenalidomide + rituximab (R2) has shown complementary clinical activity and is a tolerable regimen in both untreated and relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL), as well as mantle cell lymphoma (
Autor:
J. Li, Kathryn S. Kolibaba, Morton Coleman, Mecide Gharibo, Frederick Lansigan, Grzegorz S. Nowakowski, Jason M. Melear, Suzanne R. Fanning, Abdulraheem Yacoub, Jeffrey P. Sharman, C. Reynolds, Erin Ahn, D.J. Andorsky, Mathias J. Rummel
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S98-(2021)
Objectives Relapse is expected when treating patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a shortened response associated with each relapse. Lenalidomide combined with rituximab (R2) has shown enhanced activity, with
Autor:
Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn S. Kolibaba, Chris Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S172
Autor:
Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn S. Kolibaba, Chris Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S384
Autor:
Mecide Gharibo, Jason M. Melear, D.J. Andorsky, Morton Coleman, Mathias J. Rummel, Frederick Lansigan, J. Li, G.S. Nowakowski, Jeffrey P. Sharman, Suzanne R. Fanning, Abdulraheem Yacoub, Jung Ryun Ahn
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Journal of Clinical Oncology. 40:1573-1573
1573 Background: Clinical studies and new drug approvals are delayed by slow data transfer and transcription errors from site entered data. These delays have been compounded by a shortage of data entry personnel at sites such that data entry approach